BPC-157 and TB-500 are often discussed together for injury recovery, but neither has an FDA-approved human indication or established dosing schedule. Most BPC-157 evidence is preclinical, and TB-500 evidence in humans is even more limited. Combining them should be considered experimental and discussed with a licensed clinician, not copied from online protocols.
Wondering if peptide therapy is right for you? Take the 3-min clinical quiz.
See if you qualify →What are BPC-157 and TB-500?
BPC-157 and TB-500 are investigational synthetic peptides that people often compare for injury recovery. The short answer: they are not the same compound, and the evidence for both is much weaker than many online posts suggest.
BPC-157: a synthetic “body protection compound” peptide
BPC-157 stands for Body Protection Compound 157. It is also called BPC-157 acetate in some research and commercial settings. There is no FDA-approved brand name for BPC-157 and no established International Nonproprietary Name, or INN, for an FDA-approved medicine.
Research interest comes from animal and lab studies looking at gut injury, tendon models, ligament models, blood-vessel signaling, nitric oxide signaling, collagen-related repair, and inflammatory pathways. Reviews in sports-medicine and regenerative-medicine literature describe BPC-157 as promising but still largely preclinical, meaning it has not been proven in high-quality human trials for injury recovery 1 2.
TB-500: a synthetic fragment related to thymosin beta-4
TB-500 is commonly described as a synthetic fragment related to thymosin beta-4, a naturally occurring protein involved in actin regulation, cell migration, angiogenesis, and repair biology. Actin is part of the cell’s internal scaffolding, so it matters for how cells move and respond after injury 3 4.
TB-500 is not the same as the full thymosin beta-4 protein. It also has no FDA-approved brand name, no established FDA-approved human indication, and no FDA-approved dosing schedule. Evidence for TB-500 itself in people is limited, so broad claims about tendon, ligament, muscle, or post-surgery recovery need caution.
Why people call the combination the “Wolverine stack”
The nickname “Wolverine stack” usually means BPC-157 plus TB-500. It comes from online fitness and recovery communities, not from an FDA label or a clinical guideline. Our deeper guides on BPC-157, TB-500, and TB-500 vs BPC-157 cover each peptide separately.
What are the key facts about FDA status and evidence?
Neither peptide has an FDA-approved human use, and there is no labeled dose for either one. That matters because a forum schedule is not the same as a medical standard.
FDA approval status
BPC-157 and TB-500 are not FDA-approved drugs for human injury recovery, inflammation, wound healing, athletic performance, or post-surgical recovery. FDA’s compounding framework is separate from drug approval; being discussed for compounding does not mean a substance is FDA-approved for safety or effectiveness 5.
Human evidence level
For BPC-157, published reviews describe a body of animal and mechanistic research, with limited human evidence and no definitive human trial program for musculoskeletal recovery 1 2. For TB-500, most claims are extrapolated from thymosin beta-4 biology, cell studies, animal research, or clinical practice reports rather than large randomized human trials of TB-500 itself 3 4.
Compounding and quality concerns
Compounded BPC-157 via a 503A pharmacy, where legally permitted and clinically appropriate, is different from buying a vial from a “research chemical” website. The safer axis is licensed versus unlicensed: a licensed clinician, a patient-specific prescription, and a state-licensed pharmacy matter because injectable products raise sterility, potency, impurity, aggregation, and immunogenicity concerns 5 8.
Why online dosing protocols are not medical guidance
Because there is no FDA-approved dose, route, or cycle length for BPC-157 or TB-500, online schedules are not medical guidance. Injury diagnosis, infection risk, clotting risk, immune conditions, medications, pregnancy status, surgical plans, and sports-drug testing rules can all change the risk-benefit discussion.
Why do people combine BPC-157 and TB-500?
The theory is that BPC-157 may act more locally on repair signaling while TB-500 may support broader cell-migration biology. The honest answer is that this combination has not been proven in high-quality human trials.
The proposed theory: local tissue repair plus broader cell-migration signaling
BPC-157 research often focuses on nitric oxide pathways, angiogenesis, collagen-related healing processes, and inflammatory signaling in animal models 1. TB-500 discussions often point back to thymosin beta-4’s role in actin regulation, cell migration, angiogenesis, and wound-repair biology 3 4.
What is plausible from biology versus what is proven in humans
Biology can make a peptide idea plausible, but it does not prove human benefit. A cell moving faster in a dish, or a tendon model improving in an animal, does not tell us whether a person will recover faster, avoid surgery, return to sport sooner, or have fewer complications.
Why tendon, ligament, muscle, and post-surgery claims need caution
Tendon injury, ligament injury, muscle injury, wound healing, and post-surgical recovery are not one condition. A partial tendon strain, a complete rupture, a surgical repair, and a chronic overuse injury each need different care. Any efficacy claim about these peptides should be weighed against unknown long-term safety, injection-site reactions, product-quality concerns, and the lack of combination-specific human trials.
How do BPC-157 and TB-500 compare?
BPC-157 and TB-500 are usually compared as repair peptides, but they come from different research stories. The biggest difference is not “which one works better”; it is that neither has enough human evidence to support confident recovery claims.
| Feature | BPC-157 | TB-500 |
|---|---|---|
| Full description | Body Protection Compound 157; often sold or discussed as BPC-157 acetate | Synthetic fragment related to thymosin beta-4; often described as Ac-LKKTETQ |
| FDA-approved brand name | None | None |
| FDA-approved human indication | None | None |
| Main research focus | Animal and lab models of tissue injury, gut protection, tendon and ligament repair signaling, nitric oxide, angiogenesis, and inflammation | Thymosin beta-4-related biology: actin regulation, cell migration, angiogenesis, and wound-repair signaling |
| Human evidence | Limited; reviews describe mostly preclinical evidence rather than definitive human trials 1 2 | Very limited for TB-500 itself; many claims extrapolate from thymosin beta-4 biology 3 4 |
| Key risks | Injection-site reaction, unknown long-term safety, sterility risk, impurities, aggregation, immune reactions | Injection-site reaction, unknown long-term safety, sterility risk, impurities, aggregation, immune reactions |
| Chia availability | Not currently offered by Chia | Not currently offered by Chia |
Mechanism: angiogenesis, nitric oxide, collagen, and actin regulation
BPC-157 is often discussed in relation to angiogenesis, nitric oxide signaling, collagen formation, and inflammatory pathways. TB-500 is usually discussed through thymosin beta-4 biology, especially actin regulation and cell migration. These mechanisms are interesting, but they do not replace human outcome trials.
Evidence comparison: animal, cell, observational, and human data
The strongest evidence for either peptide is not a large human trial showing reliable injury recovery. For BPC-157, the evidence base is mostly animal and mechanistic 1 2. For TB-500, the evidence is even less direct, with much of the rationale coming from thymosin beta-4 research rather than TB-500 clinical trials.
Regulatory comparison: not FDA-approved drugs
Neither compound is an FDA-approved drug. The 503A Bulks List process is about whether a bulk substance may be used in certain patient-specific compounding settings; it is not the same as FDA drug approval for safety and effectiveness 5 6.
Is there an established dose or schedule for taking them together?
No established FDA dose exists for taking BPC-157 and TB-500 together. Any protocol that gives a fixed cycle length, vial amount, or injection schedule is not coming from an FDA-approved label.
No FDA-approved dose, route, or cycle length
FDA-approved medications have labels that define indications, routes, dose ranges, contraindications, warnings, and adverse reactions. BPC-157 and TB-500 do not have that kind of FDA-approved human label, so there is no official dose, route, or cycle length to copy.
Why clinic, forum, and “research chemical” schedules vary
Schedules vary because they are built from different assumptions: animal studies, clinician experience, supplier marketing, bodybuilding forums, or local compounding practices. That variation is exactly why a person should not treat a dosing chart online as a prescription.
Dosing-status chart: what is known, unknown, and clinician-dependent
| Question | What is known | What remains unknown or clinician-dependent |
|---|---|---|
| Is there an FDA-approved dose? | No FDA-approved dose exists for BPC-157 or TB-500. | Any dose discussion would need a licensed clinician’s review and current legal status. |
| Is there an FDA-approved route? | No FDA-approved oral, nasal, topical, or injection route exists for either peptide. | Route choice changes sterility, absorption, side-effect, and safety questions. |
| Is there a proven combination schedule? | No high-quality human trials define a BPC-157 plus TB-500 stack schedule. | Combination use adds uncertainty because overlapping risks and interactions are not well studied. |
| Can animal doses be converted into a human protocol? | Animal studies can help researchers design hypotheses. | They should not be copied by patients; animal findings do not equal human prescribing guidance. |
| Can a research-use vial be used for self-treatment? | Research-use products are not dispensed as patient-specific prescriptions. | Self-treatment raises quality, sterility, dosing, and legal risks. |
What are the possible risks and side effects?
Possible risks include injection-site reactions, sterility problems, impurities, immune reactions, peptide aggregation, and unknown long-term safety. These risks matter even when a peptide sounds “natural” or is described as a small signaling molecule.
Injection-site reactions and sterility risks
Any injected peptide can cause pain, redness, swelling, bruising, itching, or infection at the injection site. Sterility is especially important because a contaminated injectable product can introduce bacteria or other harmful material directly into tissue or the bloodstream 8.
Unknown long-term safety
Long-term human safety is not well defined for BPC-157 or TB-500. That means we do not have strong data on repeated cycles, chronic use, effects in pregnancy, effects in people with cancer history, immune conditions, clotting disorders, or complex medication lists.
Immune reactions, peptide impurities, and product-quality concerns
Peptides can degrade, aggregate, or contain impurities if manufacturing and handling are poor. FDA has identified safety concerns with some nominated bulk substances, and the agency’s compounding framework highlights why quality review matters for compounded products 5.
Can BPC-157 cause liver damage? What evidence can and cannot say
There is not enough high-quality human evidence to say BPC-157 reliably causes liver damage, and there is also not enough evidence to prove it is risk-free for the liver. If someone has liver disease, abnormal liver enzymes, heavy alcohol use, hepatitis risk, or takes liver-metabolized medications, that is a clinician-level safety discussion rather than a forum question.
How quickly does TB-500 start working?
There is no proven timeline for TB-500 to start working in humans. Online timelines are usually anecdotal, and they should not be treated as clinical trial results.
Why anecdotal timelines are not the same as clinical trial results
A person may feel better because an injury is naturally improving, physical therapy is working, pain is fluctuating, training load changed, sleep improved, or inflammation decreased for another reason. Without a controlled trial, it is hard to know what caused the change.
What animal and cell studies can suggest
Animal and cell studies can suggest that thymosin beta-4-related pathways may affect cell movement, angiogenesis, and tissue-repair signaling 3 4. They cannot prove that TB-500 will speed recovery in a person with a real-world tendon, ligament, muscle, or surgical injury.
Why injury type, rehabilitation, and diagnosis matter more than a peptide timeline
A correct diagnosis matters more than chasing a peptide timeline. A complete tendon rupture, stress fracture, infected wound, nerve injury, or failed surgical repair can worsen if someone delays proper care because they are waiting for a peptide to “kick in.”
How should patients evaluate peptide claims online?
Start with evidence level: human randomized trial, human observational data, animal study, cell study, or anecdote. The lower the evidence level, the more careful the claim should sound.
Check whether claims are based on human trials or animal/cell research
Look for plain statements about what kind of evidence supports a claim. If a site says a peptide “repairs tendons” but only cites rat models or cell studies, the accurate patient-facing wording is that it has been studied for repair signaling, not that it is proven to repair human tendons.
Avoid products sold as “for research use only” for self-treatment
Research-use products are not the same as medications prescribed for a specific patient. They may not meet the sterility, potency, testing, storage, or labeling expectations a patient should expect from a licensed medical path. Our guide to peptide group buys explains why informal sourcing adds risk.
Ask about pharmacy licensure, sterility, testing, and clinician oversight
If a peptide is being considered, the safety questions are practical: Is there a licensed clinician? Is there a real prescription? Is the pharmacy state-licensed? Is the product tested for sterility and potency? Is there follow-up if side effects occur? We cover this broader safety framework in our guide on where to get peptide injections safely.
Does Chia offer BPC-157 or TB-500?
Chia does not currently offer BPC-157 or TB-500. We are including this section clearly because patients often ask whether educational peptide articles mean a clinic offers the compound.
Chia does not currently offer BPC-157 or TB-500
At Chia, our live catalog is limited to the treatments we actually offer today. BPC-157 and TB-500 are not in that catalog, so we do not describe pricing, forms, prescribing, or treatment protocols for them.
Why Chia only describes live treatments it actually offers
This is part of how we keep education separate from access. Some peptides are educational-only because the science, legal status, or our clinic catalog does not support offering them through Chia at this time.
When to seek a licensed clinical evaluation instead of self-sourcing peptides
If you are dealing with an injury, post-surgical symptoms, persistent pain, swelling, weakness, numbness, fever, or loss of function, a licensed evaluation is the right next step. A clinician can check for problems that peptides cannot diagnose, such as rupture, infection, nerve injury, clot, medication interaction, or a rehab plan that needs to change.
FAQ
There is no proven, FDA-approved protocol for pairing BPC-157 with TB-500. The combination is commonly discussed online as the “Wolverine stack,” but it should be considered experimental because combination-specific human trials are lacking.
No. BPC-157 and TB-500 are not FDA-approved drugs and have no FDA-approved human indication, route, dose, or cycle length.
There is no established FDA-approved schedule for either peptide. Online dosing schedules should not be copied because they are not a substitute for a licensed clinician’s evaluation.
Human data are too limited to say that BPC-157 reliably causes liver damage or that it is risk-free for the liver. People with liver disease, abnormal liver tests, alcohol-related liver risk, hepatitis risk, or complex medication lists should discuss this with a clinician.
There is no proven human timeline for TB-500. Anecdotal reports are not the same as clinical trial evidence, and recovery time depends heavily on the injury, diagnosis, rehabilitation plan, and overall health.
The July 2026 PCAC vote recommended BPC-157 and TB-500 for the 503A Bulks List, but PCAC is advisory and FDA’s final determination is pending. Compounding legality depends on current FDA rules, the substance, the prescription, and the pharmacy.
No. The name refers to the combination of BPC-157 and TB-500, but it is not a proven medical treatment for injury recovery. Most support comes from mechanism-based reasoning, animal research, cell research, and anecdote.
No. Chia does not currently offer BPC-157 or TB-500. This article is educational and should not be read as an offer of treatment, pricing, or a prescribing protocol for either peptide.
References
- 1.Gwyer D, Wragg NM, Wilson SL. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal and Soft Tissue Healing. 2025.
- 2.Emerging Use of BPC-157 in Orthopaedic Sports Medicine. 2025.
- 3.Goldstein AL, Hannappel E, Kleinman HK. Thymosin beta4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005.
- 4.Philp D, Goldstein AL, Kleinman HK. Thymosin beta4 promotes angiogenesis, wound healing, and hair follicle development. Mechanisms of Ageing and Development. 2004.
- 5.U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. 2026.
- 6.U.S. Food and Drug Administration. Pharmacy Compounding Advisory Committee Meeting Materials, July 23–24, 2026.
- 7.Yoo Direct Health. FDA Peptide Update: What the Recent BPC-157, KPV, and TB-500 News Means. 2026.
- 8.U.S. Pharmacopeia. USP General Chapter <797> Pharmaceutical Compounding—Sterile Preparations. 2023.
- 9.World Anti-Doping Agency. The 2026 Prohibited List: International Standard. 2026.
- 10.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2026.
About this article
Chia Health Editorial Team — Evidence-reviewed health education
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
AI tools may assist with research and drafting. Chia's editorial team reviews source use, clarity, treatment information, and safety framing before publication. A clinician is named only after explicit sign-off. Read our editorial standards.
Get a personalized plan
See if peptide therapy is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
